Laura Joszt, MA

The accountable care organizations (ACOs) participating in the new ACO REACH model will have a health equity benchmark adjustment and need to collect more data to help better understand the populations being cared for and serve those from underserved communities, said Michael Chernew, PhD.

It’s important that patients understand the likely outcomes, problems that can occur along the way, and the risks of a treatment or procedure, explained Robert G. Fante, MD, FACS, president of the American Society of Ophthalmic Plastic & Reconstructive Surgery and facial plastic surgeon and cosmetic surgeon, Fante Eye & Face Centre in Denver, Colorado.

Weight and changes in it can indicate implications for cancer risk and cancer diagnosis, according to 2 abstracts being presented at the American Association for Cancer Research Annual Meeting.

The annual spring meeting of AMCP 2022 will include keynote sessions on health care and marketplace trends and the specialty pharmaceutical pipeline, with a featured preconference session on bias in health care.

Patients switched from the originator product maintained their clinical outcomes and remissions status while biologic-naïve patients recorded positive responses and remission outcomes after initiating infliximab-dyyb.

The Global and Professional Direct Contracting model is going to be replaced with a new accountable care organization (ACO) model, which addresses some of the pushback there had been on the direct contracting model, said Michael Chernew, PhD.

Teprotumumab has shown great efficacy in treating thyroid eye disease in both clinical trials and real-world settings, but more data are needed on adverse events, said Shoaib Ugradar, MD, UCLA Stein Eye Center Santa Monica.

Compared with placebo, dupilumab treatment resulted in statistically significant and meaningful symptom improvements in adults and adolescents with eosinophilic esophagitis (EoE), according to abstracts presenting findings from the 3-part LIBERTY-EoE-TREET study.

As a result of being less likely than men to receive lifesaving treatment when experiencing cardiogenic shock, women were significantly less likely to survive in the short and long term.

While filgrastim biosimilars had substantial uptake, there was low uptake of infliximab biosimilars. In addition, there was a lack of price competition.

A majority of patients with ophthalmic video visits were satisfied, but there were some predictors that contributed to which patients were more satisfied, explained Darren Chen, MD student at Weill Cornell Graduate School of Medical Sciences.

Minority, low-income, and elderly patients faced greater barriers to care even when it went virtual during the pandemic, according to Gregory Vidal, MD, PhD, medical oncologist specializing in breast cancer at West Cancer Center.

Quality of life for children with asthma may be influenced by psychological and sociocultural determinants of health.

People who have both severe mental illness (SMI) and obstructive airways disease (OAD) experience extraordinary disability and isolation, which leads to a lack of access to care and increased use of urgent care.

After years, the biosimilars horizon may be here with valuable opportunities to improve patient outcomes and reduce costs, said Eric Palmer, president and CEO of Evernorth.

A lack of transparency and misaligned incentives had curtailed the adoption of biosimilars in the United States.

During the COVID-19 pandemic, there has been a lot of experimentation with new technologies for remote patient monitoring (RPM) to improve adherence and survival, according to Gregory Vidal, MD, PhD, medical oncologist specializing in breast cancer at West Cancer Center.

Not all Guillain-Barré cases are associated with infection, and studies have suggested a link between the rare disorder and certain cancers, including lymphomas.

The economic burden of rare diseases based on direct, indirect, and mortality-related costs is 10 times greater than the burden for mass market diseases, such as diabetes and cardiovascular disease, and this burden increases when no treatment is available.

During an AHIP webinar, Mark Hamelburg, senior vice president of federal programs at AHIP, explained the shifts coming to Medicare and Medicaid when the public health emergency finally ends.

The supplemental new drug application (sNDA) filing includes data from 2 pivotal randomized phase 3 global studies, ALPINE and SEQUOIA, of chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL). The target action date is October 22, 2022.

The mutation is more common than expected and associated with poor outcomes, according to researchers from St. Jude Children’s Research Hospital.

AHIP released a report looking at the price markups for 10 drugs that can be delivered more affordably through specialty pharmacies, including 3 drugs with multiple biosimilars available.

The new protocol for monitoring acute lymphoblastic leukemia (ALL) is simpler than current techniques and is at least as good as the current gold standard.

The treatment was approved in October 2021 and is the first FDA-approved therapy to treat macular edema associated with uveitis via injection to the suprachoroidal space, which provides a more targeted delivery mechanism.

While the number of trials for cancer immunotherapies grew significantly, combination therapies being studied increased while monotherapies decreased.

The model identified risk factors after 6 months of treatment for the purposes of predicting overall survival and identifying which patients could benefit from a shift in treatment.

Health state utilities can be used to examine and compare the cost-effectiveness of the chimeric antigen receptor (CAR) T-cell therapies for large B-cell lymphoma (LBCL) as more become available.

A meta-analysis from 3 economists concluded that nonpharmaceutical interventions in response to COVID-19 failed to have a large, significant effect on mortality rates.

The Biosimilars Initiative in British Columbia, Canada, mandated patients with certain conditions on the province’s prescription coverage plan to switch from originator etanercept to a biosimilar.